drugset / Trial / NCT06704763
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants. The study will last up to approximately 8 weeks including screening.
Timeline
- Start
- 2024-12-06
- Primary completion
- 2025-02-05
- Completion
- 2025-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 1 mg | Oral |
| Subject | Quinidine | Small molecule | 200 mg | Oral |
| Background | Midazolam | Small molecule | 0.2 mg | Oral |
Indications
No indication recorded.